BiotechTube
Monod Bio

Monod Bio

San Francisco, United States· Est.
monod.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $8.5M

Overview

Monod Bio is a private, pre-revenue biotechnology company that emerged as a spin-out from the University of Washington's Institute for Protein Design (Baker Lab) in 2022. The company's core technology is an AI/ML platform for de novo protein design, which it applies to develop novel protein binders and biosensors, including its flagship LuxSit™ Pro luciferase. Its business model focuses on creating Research Use Only (RUO) tools and In Vitro Diagnostics (IVD) for central lab and point-of-care settings, positioning it at the intersection of AI-driven drug discovery tools and diagnostics.

Diagnostics

Technology Platform

AI/ML-powered de novo protein design platform for creating novel protein binders and biosensors with properties not found in nature.

Funding History

1
Total raised:$8.5M
Seed$8.5M

Opportunities

The company targets the large and growing life sciences tools and clinical diagnostics markets, where there is significant demand for more stable, sensitive, and reproducible protein reagents than traditional antibodies.
Its AI-driven platform allows for rapid design of custom proteins, enabling partnerships and novel diagnostic assays, particularly for point-of-care testing.

Risk Factors

Key risks include the technical challenge of reliably translating de novo protein designs into robust, commercial-grade diagnostic components and competing in markets dominated by large, established players.
The company is also dependent on securing ongoing venture funding and strategic partnerships to advance its pipeline and achieve commercialization.

Competitive Landscape

Monod Bio competes in the AI protein design space with companies like Generate Biomedicines and in the diagnostics/life sciences tools market with giants like Abbott, Roche, and Thermo Fisher. Its differentiation lies in its specific focus on de novo binders and biosensors for diagnostics, backed by its spin-out pedigree from the pioneering Baker Lab.

More companies in Diagnostics & Precision Medicine →More companies in United States →